L3VLUP
ProSign in

NVCR · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVCRVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVCR
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterNVCRVRTX
Q3 202010 holders, $3.0bn31 holders, $21.9bn
Q4 20208 holders, $4.6bn30 holders, $18.4bn
Q1 20217 holders, $3.7bn31 holders, $15.4bn
Q2 20218 holders, $7.3bn30 holders, $12.7bn
Q3 20218 holders, $3.6bn35 holders, $10.1bn
Q4 20216 holders, $2.3bn28 holders, $12.4bn
Q1 20225 holders, $2.7bn23 holders, $16.1bn
Q2 20229 holders, $2.4bn25 holders, $18.1bn
Q3 20226 holders, $3.0bn22 holders, $18.4bn
Q4 20226 holders, $2.9bn28 holders, $18.4bn
Q1 20237 holders, $2.5bn26 holders, $21.4bn
Q2 20237 holders, $1.6bn27 holders, $24.7bn
Q3 20238 holders, $329m33 holders, $24.3bn
Q4 202310 holders, $205m32 holders, $28.6bn
Q1 20249 holders, $145m31 holders, $29.8bn
Q2 20247 holders, $145m29 holders, $33.4bn
Q3 20247 holders, $142m27 holders, $33.5bn
Q4 20248 holders, $758m26 holders, $28.5bn
Q1 20256 holders, $198m21 holders, $35.4bn
Q2 20254 holders, $187m21 holders, $32.3bn
Q3 20253 holders, $43m22 holders, $25.9bn
Q4 20253 holders, $18m26 holders, $31.8bn
Q1 20262 holders, $12m25 holders, $31.8bn
Q2 20262 holders, $15m26 holders, $34.6bn
NVCR

Novocure Ltd

Holders
7
Reported value
$145m
Buyers
2
Sellers
3

Breadth -1 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
29
Reported value
$33.4bn
Buyers
12
Sellers
18

Breadth -6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NVCR (1)

Coatue Management LLC

Only VRTX (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →